The report “In-Vitro Toxicology/ Toxicity Testing Market by Industry (Diagnostic, Pharmaceutical, Cosmetics, Chemical), Technology (Cell Culture, HTS, Omics), Applications (Systemic, Dermal, Ocular),Method (Cellular Assay, Ex vivo, In Silico) - Global Forecast to 2018”, The global market will reach $17,227 million by 2018 growing at a double-digit CAGR during the forecast period (2013–2018).
Browse 67 market data tables, 25 figures spread through 246 pages and in-depth TOC on “In-Vitro Toxicity Testing Market”
Early buyers will receive 10% customization on this report.
The global market is segmented by industry, technology, method, application and geography. Based on industry, the market is further segmented into diagnostics, pharmaceuticals, chemicals, cosmetics, and food. Pharmaceutical industry secured the largest market share whereas cosmetics industry was the fastest growing industry than the rest. The inclination towards detection of toxicity during earlier stages of development is propelling the growth of pharmaceutical industry. Also, the support of regulatory authorities to use in vitro and in silico methods in place of animal testing for gathering toxicological information is driving the cosmetic industry.
Based on technology, the market is segmented into cell culture, high throughput screening, cellular imaging, and omics technologies. Cell culture technology that occupies the largest market share will also register maximum growth rate. The evolution and advancement is leading to introduction of new technologies that can better predict toxicity levels and translate in vitro results into significant in vivo effects.
Talk to Our Research Analysts for More Info@
The methods considered for the study are cellular assays, biochemical assays, ex vivo and in silico. Cellular assays held the largest market share in 2013 and the market is bound to grow at a double digit CAGR during the forecast period (2013–2018). These assays provide the capability to detect and measure cell viability, functionality, and growth. Cellular assays are used as bio markers which have capacity to predict the biological properties of potential drug compounds.
Under the applications, systemic toxicity testing was the largest segment in 2013 and will grow at the highest CAGR between 2013 and 2018. Both cardiotoxicity and liver toxicity under systemic toxicity are the key reasons for drug attrition. The increasing focus on detection of toxicity in earlier stages of development is leading to persistent requirements for human cell-based in vitro models.
Geographic analysis reveals that Europe commanded the largest share of the global in vitro toxicity testing market in 2013. This was credited to the support provided by the European government for anti-animal testing laws. The directives set by the government has further put ban on the production and sale of all animal tested cosmetics across the continent.
Globally, the market will be driven by increasing acceptance of in vitro toxicity testing methods by regulatory authorities as alternatives to in vivo testing. This has been primarily driven by demand for toxicological information on chemicals that are both existing and newly introduced into the market. The new advances in the in vitro toxicology testing have presented a wide range of new technologies that help in investigating the adverse effects of environmental agents in a more mechanistic, less expensive, and time saving manner.
Get The Sample Copy Of This Report:
Organizations such as REACH foresee that more results of in vitro and in silico methods will be included in risk assessment which will promote the use of in-vitro methods for toxicology testing. The emerging countries in Asia, such as China and India, will witness high growth on account of low cost offered by these countries as well as the economic stability observed within these countries.
The market is a highly fragmented one. The dominant players in this market are Agilent Technologies (U.S.), Alere, Inc. (U.S.), Bio-Rad (U.S.), BioReliance (Sigma Aldrich) (U.S.), Catalent Pharma Solutions (U.S.), Charles River Laboratories (U.S.), Covance (U.S.), Cyprotex (U.K.), Eurofins Scientific, Inc. (U.S.), GE Healthcare (U.K.), Life Technologies Corporation (Thermo Fisher Scientific) (U.S.), and Quest Diagnostics (U.S.).
MarketsandMarkets is world’s No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.
M&M’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
Subscribe Reports from Healthcare Domain @ http://www.marketsandmarkets.com/Subscription.html
Unit No. 802, 8th Floor,
Tower - 7, Magarpatta City SEZ,
Hadapsar, Pune – 411013,
Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/biotechnology
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets